PharmaPlanter operates a high-performance antibody engineering and development platform tailored to transform early-stage targets into validated lead candidates. Our ecosystem integrates advanced computational design with robust laboratory validation, ensuring every molecule is optimized for both biological potency and developability.

Our platform enables:

• Dual-Track Antigen Presentation: We have pioneered a unique system to overcome traditional immunization limits. Our Gas Vesicle (GV) Display effectively delivers antigens to APCs to maximize immune activation, while our Mouse Cell Expression System presents human antigens on host cell surfaces. This ensures authentic PTMs and native conformations, significantly increasing success against complex, "hard-to-target" membrane proteins.

• Fully Human Antibody Mouse Model: To accelerate clinical transition, we utilize an advanced humanized mouse model that generates fully human antibodies. By bypassing traditional murine sequence humanization, this model delivers high-affinity, low-immunogenicity candidates, providing a direct path to human-ready biologics.

• Strategic Antibody Engineering: We provide research-grade services for variable region sequencing, humanization, and affinity maturation. Using structural modeling, we refine lead molecules to minimize immunogenicity while maximizing binding specificity and biophysical stability.

• High-Resolution Kinetic Characterization: We utilize cutting-edge SPR (Surface Plasmon Resonance) and BLI (Biolayer Interferometry) technologies for real-time, label-free analysis. This allows for precise determination of Kon and Koff rates, ensuring the selection of candidates with superior binding kinetics.

• Multi-Dimensional Potency Validation: At the laboratory scale, we conduct comprehensive functional evaluations, including high-sensitivity ELISA, FACS, and cell-based bioassays. This rigorous screening confirms candidate performance and target engagement across diverse experimental conditions.

• Translational Proof-of-Concept & In Vivo Support: We bridge the gap between discovery and clinical selection through integrated animal-based in vivo studies. By conducting pilot efficacy and pharmacokinetic (PK) evaluations in humanized physiological contexts, we provide critical data to validate candidates for formal development.